Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trialReinhard Dummer, Keith T. Flaherty, Dirk Schadendorf et al.|The Lancet Oncology|2017Cited by 491
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trialAlexander Eggermont, B. Guillot, Gerald P. Linette et al.|The Lancet Oncology|2021Cited by 389
Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibilityMaria Teresa Landi, Wei V. Chen, D. Timothy Bishop et al.|Nature Genetics|2020Cited by 238
Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapyPaola Queirolo, Pietro Quaglino, Andrea Boutros et al.|Seminars in Cancer Biology|2019Cited by 119
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trialAndrew Bottomley, Daniil Stroyakovskiy, Corneel Coens et al.|The Lancet Oncology|2021Cited by 72